Ken-Ichiro Kosai
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Research Subjects
Ken-Ichiro Kosai has a total of 10 co-authors. Here are the top co-authors by number of shared publications:
Kazuo Shirouzu
Department of Surgery, Kurume University School of Medicine, Kurume, Japan
2 shared publicationsMari Fukunaga
Department of Surgery, Kurume University School of Medicine, Kurume, Japan
2 shared publicationsAkihiro Hayashi
Department of Surgery, Kurume University School of Medicine, Kurume City, Fukuoka, Japan
1 shared publicationKentaro Yuge
Department of Gene Therapy and Regenerative Medicine, Gifu University School of Medicine, Gifu, Japan
1 shared publicationSatoshi Nagano
Department of Gene Therapy and Regenerative Medicine, Gifu University School of Medicine, Gifu, Japan
1 shared publicationSetsuro Komiya
Department of Orthopedic Surgery, Kagoshima University School of Medicine, Kagoshima, Japan
1 shared publication
Latest Publications
- 1 January 2003
- Published by Wolters Kluwer Health in Hepatology
- Vol. 37 (1) , 155-163
An optimal therapeutic expression level is crucial for suicide gene therapy for hepatic metastatic cancer in mice
The most serious problem in current gene therapy is discrepancies between experimental data and actual clinical outcomes, which may be due to insufficient analyses and/or inappropriate animal models. We have explored suicide gene therapy by using various clinically relevant animal models and doubt the clinical use of maximal suicide gene expression, which has been generally recommended. To explore this subject further, we studied what expression level of suicide gene and what promoter led to the maximal clinical benefit in the case of hepatic metastatic cancer in mice. Therapeutic and adverse side effects of 4 adenoviral vectors that express herpes simplex virus thymidine kinase (HSV-tk) under different promoters were scrupulously investigated in 2 mouse models of hepatic metastasis of gastric cancer that possess clinical characteristics. Surprisingly, increases in HSV-tk expression beyond a certain point, achieved by the Rous sarcoma virus long terminal repeat promoter, not only enhanced the adverse side effects of lethal hepatotoxicity and ganciclovir-independent cytotoxicity but also failed to further increase therapeutic potential. Moreover, the carcinoembryonic antigen (CEA) tumor-specific promoter, the therapeutic potential of which had been underestimated, was much more useful—even in the case of low CEA-producing cancer—than had been previously reported. In conclusion, the optimal therapeutic expression level of a suicide gene is a novel concept and a crucial factor for successful cancer gene therapy. The present results, which contradict those of previous studies, alert researchers about possible problems with ongoing and future clinical trials that lack this concept.
- 1 January 2003
- Published by Wolters Kluwer Health in Hepatology
- Vol. 37 (1) , 155-163
An optimal therapeutic expression level is crucial for suicide gene therapy for hepatic metastatic cancer in mice
The most serious problem in current gene therapy is discrepancies between experimental data and actual clinical outcomes, which may be due to insufficient analyses and/or inappropriate animal models. We have explored suicide gene therapy by using various clinically relevant animal models and doubt the clinical use of maximal suicide gene expression, which has been generally recommended. To explore this subject further, we studied what expression level of suicide gene and what promoter led to the maximal clinical benefit in the case of hepatic metastatic cancer in mice. Therapeutic and adverse side effects of 4 adenoviral vectors that express herpes simplex virus thymidine kinase (HSV-tk) under different promoters were scrupulously investigated in 2 mouse models of hepatic metastasis of gastric cancer that possess clinical characteristics. Surprisingly, increases in HSV-tk expression beyond a certain point, achieved by the Rous sarcoma virus long terminal repeat promoter, not only enhanced the adverse side effects of lethal hepatotoxicity and ganciclovir-independent cytotoxicity but also failed to further increase therapeutic potential. Moreover, the carcinoembryonic antigen (CEA) tumor-specific promoter, the therapeutic potential of which had been underestimated, was much more useful—even in the case of low CEA-producing cancer—than had been previously reported. In conclusion, the optimal therapeutic expression level of a suicide gene is a novel concept and a crucial factor for successful cancer gene therapy. The present results, which contradict those of previous studies, alert researchers about possible problems with ongoing and future clinical trials that lack this concept.
- 1 June 2002
- Published by Elsevier in The Annals of Thoracic Surgery
- Vol. 73 (6) , 1740-1746
Adenoviral herpes simplex virus thymidine kinase gene therapy in an orthotopic lung cancer model
- 1 June 2002
- Published by Elsevier in The Annals of Thoracic Surgery
- Vol. 73 (6) , 1740-1746
Adenoviral herpes simplex virus thymidine kinase gene therapy in an orthotopic lung cancer model